Impact of Age and Comorbidity on Treatment and Outcomes in Elderly Cancer Patients
Section snippets
Age and Comorbidity on Receipt of Aggressive Cancer Treatment
A significant proportion of elderly cancer patients do not receive curative-intent treatments.4, 8, 16, 17, 18, 19, 20 In an analysis of data from the Surveillance, Epidemiology, and End Results-Medicare linked database (SEER-Medicare), approximately 50% of Medicare patients with high-risk prostate cancer did not receive curative therapy concordant with published guidelines.21 Although early prostate cancers are often slow growing and could be followed conservatively, high-risk prostate cancer
Disease Control and Survival Outcomes from Aggressive Treatment in Elderly Cancer Patients
Several studies have examined the potential benefit of aggressive oncological treatments in elderly patients. In a randomized trial of patients aged 70 years or older with stage IIIB or IV non–small-cell lung cancer, patients were assigned to receive vinorelbine (Navelbine, Pierre Fabre Pharmaceuticals, Inc, France) alone versus polychemotherapy with vinorelbine and gemcitabine (Gemzar, Eli Lilly and Co, Indianapolis, IN).43 Polychemotherapy was associated with an improved overall survival
Age and Comorbidity on Treatment-Related Toxicity
Data are mixed regarding whether older patients experience increased treatment-related toxicity compared with younger patients. Pignon et al65 examined the acute and late toxicity from thoracic radiation therapy in a combined analysis of 1,208 lung and esophageal cancer patients treated on 6 European Organization for Research and Treatment of Cancer clinical trials. Patients were analyzed in age-groups ranging from <50 to >70 years. Age was not significantly associated with acute (including
Age and Comorbidity on Patient-Reported Outcomes and HRQOL
HRQOL is increasingly recognized as an important outcome following all forms of cancer treatment and provides patient-centered information that is complementary to physician-assessed toxicity.78, 79 Comorbidities adversely affect the quality of life of cancer patients. In a study of 195 cancer patients older than 60 years, Wedding et al80 measured HRQOL before initiation of chemotherapy. Patients with comorbidities had significantly lower baseline HRQOL, which persisted on multivariable
Summary and Knowledge Gaps
Multiple studies have demonstrated that elderly cancer patients are less likely to receive aggressive treatment, even those with little or no baseline comorbidity. The published literature suggests that in selected elderly patients, including those enrolled on clinical trials, aggressive treatment can provide similar disease control and survival benefit as that for younger patients. There is concern about potentially increased treatment-related toxicity and adverse quality of life effects in
References (89)
- et al.
Treatment of muscle invasive bladder cancer: Evidence from the national cancer database, 2003 to 2007
J Urol
(2011) - et al.
Patterns of care for the treatment of bladder cancer
J Urol
(2003) - et al.
Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study
Eur J Cancer
(2005) - et al.
The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: A population-based study
Eur J Cancer
(1992) - et al.
Factors influencing treatment patterns of breast cancer patients age 75 and older
Crit Rev Oncol Hematol
(2003) - et al.
Breast cancer in elderly women: A different reality?Results from the NORA study
Ann Oncol
(2007) - et al.
Patterns of care in elderly head-and-neck cancer radiation oncology patients: A single-center cohort study
Int J Radiat Oncol Biol Phys
(2011) - et al.
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial
Lancet
(2009) - et al.
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy
Urology
(2009)
Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study
J Urol
Age has no impact on acute and late toxicity of curative thoracic radiotherapy
Radiother Oncol
Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer
Urology
Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response
Int J Radiat Oncol Biol Phys
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy
J Urol
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
J Urol
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy
Eur J Cancer
Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature
Eur Urol
Which chronic conditions are associated with better or poorer quality of life?
J Clin Epidemiol
Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms
Mayo Clin Proc
The effect of comorbidity on quality of life during radiotherapy in head and neck cancer
Otolaryngol Head Neck Surg
Radiation therapy in the elderly
Cancer J
Cancer statistics, 2010
CA Cancer J Clin
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden
Cancer
Time trends and local variation in primary treatment of localized prostate cancer
J Clin Oncol
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States
J Natl Cancer Inst
Trends in the treatment of localized prostate cancer using supplemented cancer registry data
BJU Int
Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease?A patterns of care study using the surveillance epidemiology and end results database
Int J Radiat Biol Phys
Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database
J Clin Oncol
Population-based trends in use of surgery for non-small cell lung cancer in a UK region, 1995-2006
Thorax
Cancer burden in the aged: An epidemiologic and demographic overview
Cancer
Cancer survivors in the United States: Age, health, and disability
J Gerontol A Biol Sci Med Sci
Cancer, comorbidities, and health-related quality of life of older adults
Health Care Financ Rev
Age and adjuvant chemotherapy use after surgery for stage III colon cancer
J Natl Cancer Inst
Choice of cancer therapy varies with age of patient
JAMA
Cancer-directed surgery for localized disease: Decreased use in the elderly
Ann Surg Oncol
Determinants of cancer therapy in elderly patients
Cancer
The influence of patient age on the diagnosis and treatment of lung and colorectal cancer
Arch Intern Med
Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study
J Clin Oncol
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
JAMA
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older
JAMA
Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival
J Clin Oncol
Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical influences
Cancer
Cancer treatment and age: Patient perspectives
J Natl Cancer Inst
Cited by (0)
Supported in part by a grant from the Doris Duke Charitable Foundation to the University of North Carolina at Chapel Hill to fund Clinical Research Fellow Trevor Royce, MS.